05.22.25 -- Your Next CDMO Partner Could Be Just A Click Away

In this presentation, we will highlight how our proven expertise and simplified execution with development, filling, and analytical under one roof ensure safe, efficacious products reach patients in need.

Sr. Director of Commercial Operations, Tara Lorenz, speaks on our latest investments and expanded fill/finish capabilities and capacity for small molecules, biologics, and other sterile injectable products.

With expertise in process optimization, analytics, and regulatory strategy, we help partners de-risk development, accelerate time to market, and ensure manufacturability from the outset.

Backed by years of dedication to customer-focused solutions, we’re proud to introduce our specialists to the global biopharma community and share insights that drive innovation forward.

Evan Pasenello, Head of Commercial Services, gives viewers an update on how we can support manufacturing programs from clinical through commercial.

Discover how proven sterile fill-finish expertise, high-potency capabilities, and customizable cleanrooms can support your product from development to commercialization.

Sr. Key Account Manager, Dr. Jürgen Lübbehusen, highlights our overall fill-finish capabilities and capacities, with a focus on our ability to help meet your complex needs.

Executive Director of Technology and Business Development for Drug Product and Finished Goods, Henrik Herrmann, shares an update on the current and future state of FDB’s capabilities.

Advance your clinical and commercial programs with expert aseptic fill finish and formulation services across vials, cartridges, and syringes, all in state-of-the-art, EU Annex 1-compliant facilities.

President of Snapdragon Chemistry and Chief Scientific Officer, Matthew Bio, Ph.D., presents the company’s capabilities in the development of peptide therapeutics.

Leverage expert small molecule solutions from preclinical development to commercial manufacturing, with strengths in large-scale oral solids, advanced formulations, and more.

Join Executive Director of Business Development, Nicholas Duda, as he highlights our available capacity across North America, Europe, and Asia, and our unique capabilities.

Learn how our nearly 50 years of expertise in oral solid dosage manufacturing and packaging can support your project with cutting-edge services and expanding capacity to meet your needs.

Uncover how Integrated Unprocessed Bulk testing — including viral assays, NGS, and TEM — can safeguard product safety, minimize contamination risks, and streamline biologics development.

Caddy Hobbs, Ph.D., takes an in-depth look at our analytical services, which support the full drug development lifecycle — from early development through to commercial manufacturing.

Gain a strategic edge through customized solutions, reliable metrics, and a clear pathway to successful downstream testing, ensuring your therapeutics reach patients faster.

Accelerate your drug development and ensure regulatory compliance with our innovative analytical solutions and advanced nitrosamine testing strategies.

Get the quality, compliance, and accelerated development support you need for your small molecule and cell and gene therapy program with our advanced analytical testing services.

This presentation offers a global overview of our comprehensive ADC program, providing developers with full end-to-end support — all under a single, streamlined contract.

Our integrated expertise can help you develop and manufacture dual payload ADCs with optimized efficacy, precision conjugation, and scalable solutions.

Consider how our end-to-end ADC solutions — from advanced conjugation technologies to scalable manufacturing — can accelerate your therapeutic development.

Witness how proven expertise and expanding capabilities in ADC manufacturing can help you scale high-value injectable therapies with speed, quality, and regulatory confidence.